CJC-1295 DAC is a long-acting growth hormone-releasing hormone (GHRH) analog developed to stimulate the body’s natural production of growth hormone and insulin-like growth factor-1 (IGF-1). Clinical research has demonstrated its ability to promote sustained elevations in growth hormone levels, making it a significant focus in endocrine, metabolic, and healthy aging investigations. The inclusion of Drug Affinity Complex (DAC) technology extends its half-life, enabling prolonged biological activity and enhanced research potential. In fitness and performance-focused applications, CJC-1295 DAC has gained considerable attention for its potential role in supporting recovery, body composition management, protein synthesis, exercise adaptation, and restorative sleep quality. Its unique pharmacokinetic profile continues to make it one of the most extensively researched peptides in growth hormone optimization and longevity science.